Kurt E Amrein

This inventor holds 29 USPTO granted patents and 1 published patent application, plus 6 CIPO patents and 23 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Hoffmann-La Roche Inc.. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kurt E Amrein. Retrieved from https://idiyas.com/inventor/kurt-e-amrein

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 1)

% Patents Active = 62.1

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 23 (Patent Applications = 24)

Average Co-Inventor Count = 7.5

ph-index = 4

Forward Citations = 38(Granted Patents)

Location History:

Itingen, CH (2009 - 2018)
Basel, CH (2021)

Company Filing History:

29 out of 5,026

Hoffmann-La Roche Inc.

patents

Years Active: 2009-2021

Loading Chart...

Areas of Expertise:

Aldosterone Synthase Inhibitors

Anti-bacterial Peptides

Dihydroquinoline Compounds

Phenyl-Dihydropyridine Derivatives

Isoquinoline Compounds

Tetrahydrocinnoline Derivatives

Imidazolone Derivatives

Pyridazine Derivatives

Pyrazolones

Diabetes Treatment

11b-HSD1 Inhibitors

Spirodiamine Derivatives

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11066443 - Anti-bacterial peptide macrocycles and use thereof (2021-07-20),

2. 10035804 - Spirodiamine derivatives as aldosterone synthase inhibitors (2018-07-31),

3. 9796726 - Dihydroquinoline pyrazolyl compounds (2017-10-24),

4. 9796702 - Dihydroquinoline pyrazolyl compounds (2017-10-24),

5. 9790217 - Pyridinyloxy- and phenyloxy-pyrazolyl compounds (2017-10-17),

6. 9790200 - Dihydroquinoline pyrazolyl compounds (2017-10-17),

7. 9695152 - 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds (2017-07-04),

8. 9695151 - 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds (2017-07-04),

9. 9636339 - Phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors (2017-05-02),

10. 9636338 - Phenyl-dihydropyridine derivatives as inhibitors of aldosterone synthase (2017-05-02),

11. 9593107 - Dihydroquinoline-2-one derivatives (2017-03-14),

12. 9505742 - 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds (2016-11-29),

13. 9464058 - Imidazolylketone derivatives (2016-10-11),

14. 9458135 - Dihydroquinoline-2-one derivatives (2016-10-04),

15. 9353081 - Bicyclic dihydroquinoline-2-one derivatives (2016-05-31),

Title: Kurt E Amrein: Pioneering Innovations in Pharmaceutical Chemistry

Introduction: Kurt E Amrein is a prominent inventor based in Itingen, Switzerland, known for his substantial contributions to pharmaceutical chemistry, particularly in the development of novel compounds. With an impressive portfolio of 29 patents, he continues to push the boundaries of innovation in the industry.

Latest Patents: Among his latest contributions are groundbreaking patents such as the "Anti-bacterial peptide macrocycles and use thereof," which explores new compounds capable of combating bacterial infections. Another significant invention is focused on "Spirodiamine derivatives as aldosterone synthase inhibitors." This invention provides novel compounds defined by specific structural formulas, along with compositions and methods for their application in medical treatments.

Career Highlights: Kurt E Amrein is affiliated with Hoffmann-La Roche Inc., a leading company in the pharmaceuticals sector, where he has developed numerous innovative solutions to complex health challenges. His dedication to research and development has positioned him as an influential figure within his field.

Collaborations: Collaboration has been a key aspect of Kurt's success, working alongside esteemed colleagues such as Bernd Kuhn and Alexander Mayweg. These partnerships have fostered an environment of creativity and innovation, leading to significant advancements in pharmaceutical research.

Conclusion: Kurt E Amrein exemplifies the spirit of innovation in the pharmaceutical industry with his diverse range of patents. His work not only highlights the importance of collaborative efforts but also showcases the potential for new therapeutic solutions that can significantly improve health outcomes.

Profile summary based on public USPTO records.